Research and Markets: The Cardiovascular Market Outlook to 2008:.Business Editors DUBLIN, Ireland--(BUSINESS WIRE)--April 28, 2004 Research and Markets (http://www.researchandmarkets.com) has announced the addition of The Cardiovascular cardiovascular /car·dio·vas·cu·lar/ (-vas´ku-ler) pertaining to the heart and blood vessels. car·di·o·vas·cu·lar adj. Abbr. Market Outlook to 2008 to their offering. The Cardiovascular Market Outlook to 2008, is a comprehensive source of market analysis of the most valuable therapy area within the global pharmaceutical market Valued at an estimated $73.7bn in 2002, the global market for cardiovascular drugs grew by a moderate 2.5% over 2001 levels. But how much do you know about the fastest growing cardiovascular (CV) segment? Who has the fastest growing CV portfolio? And how will the market develop in the next five years? All these questions and more are answered in this management report. This report provides detailed analysis of patient pool potential, sub-markets, leading companies' strategies, key industry developments and potential CV blockbusters of the future. With this analysis you will be able to identify areas for investment and develop strategies to counter any upcoming threats to your CV drug portfolio. Lifecycle management strategies are also becoming as important as product innovation in maintaining and building market shares and revenues. Understand how leading companies are maximizing lifecycle management strategies to extend revenue streams within the cardiovascular market with this new report. Top five reasons to buy this report - Analyze the recent performance of drugs in each therapeutic class of the global cardiovascular market. - Understand how the competitive landscape may be changed by the results of clinical trials such as CURE, LIFE, ALLHAT ALLHAT Cardiology An ongoing randomized, open label, multicenter trial evaluating whether antihypertensive therapy reduces M&M in CAD, and to determine whether lipid-lowering pravastatin therapy in moderately hypercholesteremic Pts reduces heart-related M&M. and HOPE. - Assess the strength of leading players' cardiovascular portfolios and identify how they are positioning themselves to maintain and build franchise revenues. - Quantify Quantify - A performance analysis tool from Pure Software. your products' market potential in the cardiovascular market by evaluating the patient base in different therapeutic classes. - Benchmark the performance and potential of future cardiovascular blockbuster drugs A blockbuster drug is a drug generating more than $1 billion of revenue for its owner each year. The search for blockbusters has been the foundation of the R&D strategy adopted by big pharmaceutical companies, but this looks set to change. from compounds currently in development, including third generation statins Statins A class of drugs commonly used to lower LDL cholesterol levels. Mentioned in: C-Reactive Protein , new anti-hypertensives and an oral anti-coagulant. Leading players in the cardiovascular market Summary Introduction Global market shares Pfizer Marketed products R&D compounds Cardiovascular portfolio sales forecasts Sales forecast A key input to a firm's financial planning process. External sales forecasts are based on historical experience, statistical analysis, and consideration of various macroeconomic factors. Merck & Co. Marketed products R&D compounds Cardiovascular portfolio sales forecasts Bristol-Myers Squibb Bristol-Myers Squibb (NYSE: BMY), colloquially referred to as BMS, is a pharmaceutical corporation, formed by a 1989 merger between pharmaceutical companies Bristol-Myers Company, founded in 1887 by William McLaren Bristol and John Ripley Myers in Clinton, NY (both were Marketed products R&D compounds Cardiovascular portfolio sales forecasts Novartis Marketed products R&D compounds Cardiovascular portfolio sales forecasts AstraZeneca Marketed products R&D compounds Cardiovascular portfolio sales forecasts Aventis Marketed products R&D compounds Cardiovascular portfolio sales forecasts Drug profiles Exanta (ximelagatran/melagatran) Drug overview Clinical trials Drug indications Patient potential Marketing capabilities Blockbuster block·bust·er n. 1. Something, such as a film or book, that sustains widespread popularity and achieves enormous sales. 2. A high-explosive bomb used for demolition purposes. 3. potential Crestor Cres·tor A trademark for the drug rosuvastatin calcium. rosuvastatin calcium Crestor Pharmacologic class: HMG-CoA reductase inhibitor Therapeutic class: Antilipemic (rosuvastatin) Drug overview Clinical trials Market potential Sales and marketing capabilities Pitavastatin Drug overview Clinical trials Market potential: home and away Benicar (olmesartan) Overview Clinical trial data Side-effects Requirement for further trials against irbesartan irbesartan /ir·be·sar·tan/ (ir?be-sahr´tan) an angiotensin II receptor antagonist used as an antihypertensive. ir·be·sar·tan n. and candesartan candesartan /can·de·sar·tan/ (kan?de-sahr´tan) an angiotensin II receptor antagonist, used in the treatment of hypertension; administered orally as c. cilexetil. Patient potential Marketing factors Strategic analysis and blockbuster rating Norvasc/Lipitor (amlodipine/atorvastatin) single pill Overview Potential for cross-risk factor single pill combinations Likelihood of approval Patient potential Eplerenone Drug overview Clinical trial data Side effect profile Potential in heart failure Patient potential Marketing potential: the Pfizer effect For more information visit http://www.researchandmarkets.com/reports/c1611 |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion